Efficacy of low-dose methimazole in control of multiple relapses of Graves’ hyperthyroidism: a case report

INTRODUCTION: Methimazole (MMI) is the treatment of choice for patients with Graves’ disease. The major drawback of this treatment is the relapse of hyperthyroidism in half of the patients after discontinuation of the recommended conventional 12–18 months of MMI treatment. TSH receptor antibody (TRA...

Descripción completa

Detalles Bibliográficos
Autores principales: Azizi, Fereidoun, Amouzegar, Atieh, Abdi, Hengameh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063397/
https://www.ncbi.nlm.nih.gov/pubmed/33888159
http://dx.doi.org/10.1186/s13256-021-02788-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063397/
https://www.ncbi.nlm.nih.gov/pubmed/33888159
http://dx.doi.org/10.1186/s13256-021-02788-4

Ejemplares similares